Enovis Corporation (NYSE:ENOV) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Enovis Corporation (NYSE:ENOV) have earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $40.3750.

ENOV has been the topic of a number of recent analyst reports. Wells Fargo & Company reduced their price objective on Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Canaccord Genuity Group cut their price target on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research report on Tuesday, September 1st. Finally, BTIG Research dropped their target price on shares of Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, September 1st.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert bought 2,660 shares of the business’s stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the transaction, the insider owned 63,898 shares in the company, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the purchase, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 23,293 shares of company stock valued at $449,599. 2.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc increased its holdings in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after purchasing an additional 1,174 shares during the last quarter. Allworth Financial LP acquired a new position in shares of Enovis during the 2nd quarter worth about $36,000. Integrated Wealth Concepts LLC bought a new stake in shares of Enovis in the 2nd quarter valued at about $39,000. Public Employees Retirement System of Ohio bought a new stake in shares of Enovis in the 2nd quarter valued at about $48,000. Finally, Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Enovis by 468,400.0% in the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company’s stock valued at $107,000 after acquiring an additional 4,684 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Enovis Price Performance

Shares of Enovis stock opened at $18.03 on Friday. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -0.94 and a beta of 1.31. The firm’s 50-day moving average price is $24.55 and its two-hundred day moving average price is $23.90. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis has a 1-year low of $17.30 and a 1-year high of $34.28.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. Enovis’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.